已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Editorial comments on “Early initiation of short‐term emollient use for the prevention of atopic dermatitis in high‐risk infants—The STOP‐AD randomized controlled trial”—Is emollient therapy enough?

医学 特应性皮炎 过敏性 随机对照试验 过敏 累积发病率 食物过敏 入射(几何) 儿科 哮喘 皮肤病科 内科学 免疫学 队列 物理 光学
作者
Helen A. Brough,Sayantani B. Sindher,Kari C. Nadeau
出处
期刊:Allergy [Wiley]
卷期号:78 (4): 908-911
标识
DOI:10.1111/all.15626
摘要

Early onset, severe atopic dermatitis (AD) is the strongest risk factor for the development of food allergy in children. The Dual Allergy Exposure Hypothesis proposes that there is a narrow window of opportunity where allergen exposure first through the skin versus the gut leads to food allergy. There is a growing body of literature on primary prevention of AD as a strategy to prevent transcutaneous sensitization and food allergy. Zhong et al.1 found that preventive emollient therapy was effective in high-risk infants (with parental history of atopy) and in participants where there was no cessation of the emollient before assessment of AD. If emollients could prevent the duration of eczema, this could give more time for parents to introduce allergenic foods.2, 3 (Figure 1). In the recent publication of “Early initiation of short-term emollient use for the prevention of atopic dermatitis in high-risk infants – The STOP-AD randomized controlled trial,” Ní Chaoimh et al. published the findings from a single-center clinical trial. The STOP-AD recruited 321 term high-risk infants (parental history of AD, asthma, or allergic rhinitis) that were randomized to either twice-daily Aveeno® Dermexa fast & long-lasting balm for 8 weeks or routine skin care.4 The primary outcome was cumulative AD incidence, defined by meeting the UK Working Party Diagnostic Criteria (UKWPDC), at 12 months of age. Point prevalence of AD was 38.2% in the control arm versus 20.5% in the intervention arm (p = .003), and cumulative incidence at 12 months was 46.4% in the control arm versus 32.8% in the intervention arm (p = .036). There was no difference in skin infections between groups: 5% (6/120) in the intervention group versus 5.7% (8/140) control group. No significant differences in transepidermal water loss (TEWL) were noted between the intervention and control group at birth, 2, 4, and 8 weeks, or at 6 and 12 months. Although this study was not powered to determine food allergic outcomes, food allergy testing was based on history on history of consumption and sensitization assessed via skin prick testing (SPT) at 12 months of age for milk, egg, and peanut. There was no significant difference between groups with a positive SPT to at least one allergen reported in 3.3% (4/120) in the intervention group and 3.6% (5120) in the control group (p = 1.0), although this study was not powered to determine food allergic outcomes. There was no measure of environmental food exposure, which is a known risk for the development of food allergy.2 Analysis of microbiome diversity and inflammatory biomarkers is being performed in a subset of patients. Limitations in the study design include that AD assessment was often done remotely and monitoring of adherence was performed only via parental reporting. The STOP-AD study differed from other prevention studies (Table 1) primarily in its short duration of treatment (2 months) at a very early age (median 3.5 days), high parental reported adherence rate to the emollients (82.4% >5 days/week at least once daily) and low “contamination” of the control arm (80% used emollient ≤3 days a week). The high adherence is likely due to the short duration of treatment. In recent large RCTs, BEEP, and PreventADALL, where emollients were used for the first year, no protective effect was found. However, the emollients were initiated later with a median age of 11 days in BEEP and initiation at 2 weeks of age in PreventADALL.5 STOP-AD trial was primarily conducted in Caucasians so it would be important to ascertain whether this treatment is effective in prevention of AD in non-Caucasians, especially given that food allergy can develop early in non-Caucasians.6 Type of emollients can also play a role in the response. In BEEP, a petroleum-based formulation and in PreventADALL a paraffin-based formulation were used. A prior publication (PEBBLES Pilot study)7 has shown a promising results toward the improved response of AD in response to ceramide containing emollients and the PEBBLES study is underway (https://clinicaltrials.gov/ct2/show/NCT03667651). Frequency and surface area application of the emollient could also matter. In Table 1, we present a description and comparison of other randomized controlled trials for the primary prevention of AD using emollients.1, 5, 8 The investigators cited increased transepidermal water loss (TEWL) from birth to 2 months and followed by stabilization as the rationale for the study based on their prior publications; however, no changes in TEWL were noted between the intervention group or control group at any of the time points. Our group has shown that even short-term use of a creams (both trilipid cream and paraffin-based emollient) can decrease TEWL after just 5 weeks of use.9 Based on the outside-in hypothesis, barrier enhancement may be sufficient to prevent AD; however, in the inside-out hypothesis whether anti-inflammatory agents are required to address the skewed immune response remains to be seen (Figure 1). Future directions in this field include combination of emollient with anti-inflammatory topical treatments. Treatment of dry skin or eczema with emollients and topical steroids is currently under evaluation in the PACI (Prevention of Allergy via Cutaneous Intervention: UMIN-CTR: UMIN000028043) and SEAL (Stopping Eczema and Allergy Study: https://clinicaltrials.gov/ct2/show/NCT03742414 study). Future implications of the STOP-AD study findings are profound. This is a simple, cheap, short intervention that could potentially affect the progression of the allergic march. It will be important to assess the impact of the prevention of AD on food sensitization and allergy. All authors contributed equally to the writing of the manuscript. We thank Dr. Vanitha Sampath for preparing the manuscript for submission. None. Dr. Sindher reports grants from NIH, Regeneron, DBV Technologies, Aimmune, Novartis, CoFAR, and FARE. She is an Advisory member at Genentech and DBV Technologies. Dr. Nadeau reports grants from National Institute of Allergy and Infectious Diseases (NIAID), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Environmental Health Sciences (NIEHS), and Food Allergy Research & Education (FARE); stock options from IgGenix, Seed Health, ClostraBio, and ImmuneID; is Director of the World Allergy Organization Center of Excellence for Stanford, Advisor at Cour Pharma, Consultant for Excellergy, Red tree ventures, Eli Lilly, and Phylaxis, Co-founder of Before Brands, Alladapt, Latitude, and IgGenix; and National Scientific Committee member at Immune Tolerance Network (ITN), and National Institutes of Health (NIH) clinical research centers, outside the submitted work; patents include, “Mixed allergen composition and methods for using the same,” “Granulocyte-based methods for detecting and monitoring immune system disorders,” and “Methods and Assays for Detecting and Quantifying Pure Subpopulations of White Blood Cells in Immune System Disorders.” Dr. Brough reports research grants from National Institute of Allergy and Infectious Diseases (NIAID), Aimmune and DBV Technologies, speaker honoraria from DBV, Sanofi and GSK outside of the submitted work.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
FadedTulips完成签到 ,获得积分10
刚刚
xinyuanjia的应助被一彤展翅采纳,获得30
1秒前
联联完成签到 ,获得积分10
2秒前
健康的紫文完成签到,获得积分10
2秒前
3秒前
3秒前
3秒前
小菜鸡完成签到,获得积分10
6秒前
奇迹发布了新的文献求助10
9秒前
ella333发布了新的文献求助30
10秒前
风中的宛白的应助被hulai采纳,获得10
10秒前
12秒前
烟花的应助被area采纳,获得10
12秒前
慕青的应助被黎明采纳,获得10
12秒前
Parsee的应助被卤一碗芋头糕采纳,获得10
14秒前
季夏聆风吟完成签到 ,获得积分10
15秒前
李金成完成签到 ,获得积分20
17秒前
19秒前
乐羽乐完成签到,获得积分10
20秒前
Luo完成签到 ,获得积分10
20秒前
21秒前
ella333完成签到,获得积分10
21秒前
area发布了新的文献求助10
24秒前
流萤晓成眠完成签到,获得积分10
24秒前
骆十八完成签到,获得积分10
25秒前
无极微光的应助被外向含之采纳,获得30
25秒前
25秒前
乐乐的应助被爱you采纳,获得10
25秒前
26秒前
26秒前
27秒前
晴明墨之介完成签到,获得积分10
28秒前
赘婿的应助被CHean采纳,获得20
28秒前
轩天完成签到,获得积分10
29秒前
小清完成签到,获得积分10
29秒前
30秒前
学霸业的应助被奇迹采纳,获得10
30秒前
烟花的应助被不安的彤采纳,获得10
31秒前
超级白玉发布了新的文献求助10
32秒前
热心剑成完成签到,获得积分10
32秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179547
求助须知:如何正确求助?哪些是违规求助? 9569910
关于积分的说明 21807373
捐赠科研通 7775016
什么是DOI,文献DOI怎么找? 3433072
关于科研通互助平台的介绍 2556999
邀请新用户注册赠送积分活动 2478760